🟢 Alpha Cognition is trading 10.8% up today after Raymond James initiates with Outperform rating and $20 price target

Alpha Cognition is trading 10.8% up at $9.42 after Raymond James initiated coverage with an Outperform rating and a $20 price target, highlighting significant upside for its Alzheimer’s drug ZUNVEYL.

• Analysts labeled the stock as undervalued relative to its fair value, citing a constructive fundamental story driven by ZUNVEYL’s commercialization and strong Q1 2026 revenue.
• The company is seeing continued momentum from its ongoing RESOLVE Phase 4 study enrollment, further validating the long-term growth prospects for its lead therapeutic.